Sangamo Therapeutics (0R1D.L) stock: Winston Score, insiders and Congress trades

Sangamo Therapeutics is a biotechnology company that works on gene editing and gene therapy — technologies that try to fix diseases by changing or repairing DNA inside the body. Its main focus areas include rare genetic diseases, neurological conditions, and blood disorders. The company uses a proprietary gene-editing tool called zinc finger nucleases (ZFNs), which it developed in-house and licenses to other drugmakers. Sangamo makes money in two main ways: licensing its ZFN technology to pharmaceutical partners like Biogen and Novartis, and advancing its own pipeline of experimental therapies. It is based in the United States and operates at a small scale, with a market cap of roughly $100 million. The company spends far more than it earns — its deeply negative operating margin reflects a pipeline still in clinical trials with no approved products generating meaningful revenue. The biggest risk is running out of cash before any of its therapies reach approval, which is a common and serious challenge for small-cap biotech companies.

Editorial rules set and reviewed by Felix Prehn, Economist and Editor. Figures are refreshed daily from Financial Modeling Prep and company filings; last refreshed 2026-10-11.